| ¿µ¹® | dumping syndrome | ÇÑ±Û | ´ýÇÎÁõÈıº |
|---|---|---|---|
| ¼³¸í | ºÎºÐÀû À§ÀýÁ¦¼ú ¶Ç´Â À§ºóâÀÚ¿¬°á¼úÀ» ¹ÞÀº ȯÀÚ¿¡°Ô¼ À½½ÄÀ» ¸ÔÀº ÈÄ¿¡ ÀϾ´Â ÁõÈıºÀÌ´Ù. ¸íÄ¡ ºÎºÐÀÇ ÆØ¸¸°¨°ú ¾Ð¹Ú°¨-±¸¿ª-±¸Åä µîÀÇ º¹ºÎÁõ»ó ¿Ü¿¡ Å»·Â°¨-Çö±âÁõ-¹ßÇÑ-°¡½¿¶ê µî ¼øÈ¯Àå¾Ö Áõ»óÀÌ µû¸¥´Ù. ±×·± Áõ»óÀº ¼·ÃëÇÑ À½½Ä¹°ÀÌ À§¿¡¼ ÀÛÀºÃ¢ÀÚ·Î Ãß¶ôÇÏµí ¹èÃâµÊÀ¸·Î½á À½½Ä¹°ÀÇ ¹«°Ô·Î ÀÎÇØ ¼ÒȰüÀÌ ¾Æ·¡ÂÊÀ¸·Î ÃÄÁ®µç´Ù. ÀÛÀºÃ¢ÀÚº®ÀÌ ±Þ°ÝÇÏ°Ô ´Ã¾î³ªµç°¡, ÈÇÐÀû ÀÚ±ØÀ¸·Î ÀÎÇÑ ÀÛÀºÃ¢ÀÚº®ÀÇ ÀÚÀ²½Å°æ¹Ý»ç, ÀÛÀºÃ¢ÀÚº®ÀÇ »ïÅõ¾Ð¿¡ ÀÇÇØ ¼ÒȰüÀ¸·Î ¼öºÐÀÌ ±Þ¼ÓÈ÷ ´ë·® À̵¿ÇÏ¿© ¼øÈ¯µÇ´Â Ç÷¾×ÀÇ ¾çÀÌ °¨¼ÒÇÏ¿© ÀϾÙ. ÁÖ·Î ½Ä»ç¿ä¹ýÀ¸·Î Ä¡·áÇÏ¿©, ¾à¹°¿ä¹ýÀ¸·Î´Â ¾ÆÆ®·ÎÇÉ-Çí»ç¸ÞÅä´½-Æä³ë¹Ù¸£ºñÅ»-ź»ê¼ö¼Ò³ªÆ®·ýÀÇ »ç¿ë ¹× Æ÷µµ´çÁֻ絵 È¿°ú°¡ ÀÖ´Ù. ¼ö¼ú¿ä¹ýÀº ºô·Î½º(Billroth) Á¦1¹ýÀ¸·ÎÀÇ º¯È¯, ´ë¿ëÀ§ÀÇ Á¦ÀÛ µîÀÌ ÀÖÀ¸³ª È®½ÇÇÑ °ÍÀº ¾Æ´Ï´Ù. |
||
| ¿µ¹® | Raynaud syndrome | ÇÑ±Û | ·¹À̳ëÁõÈıº |
|---|---|---|---|
| ¼³¸í | »çÁöÀÇ ´ëĪÀû û»öÁõÀ» Ư¡À¸·Î ÇÏ´Â Áõ»óÀ¸·Î¼ ¼Õ°¡¶ô-¼Õ¸ñ µîÀÇ ÇǺΰ¡ Áö¼ÓÀûÀ¸·Î û»ö°ú Àû»öÀ¸·Î º¯Çϰí, ¼Õ°¡¶ôÀÇ ´ë·® ¶¡³²°ú ³Ã°¢À» ¼ö¹ÝÇÑ´Ù. |
||
| ¿µ¹® | battered child syndrome | ÇÑ±Û | ¸Å¸Â´Â ¾ÆÀÌ ÁõÈıº |
|---|---|---|---|
| ¼³¸í | ¿µÀ¯¾Æ³ª ¼Ò¾Æ°¡ ºÎ¸ð µîÀÇ º¸À°ÀÚ³ª ÇüÁ¦ÀڸŷκÎÅÍ ¹Ýº¹Çؼ ½ÅüÀûÀÎ Çд븦 ¹Þ¾Æ ¹ß»ýÇÏ´Â °¢Á¾ Áõ»çÀÇ ÃÑĪÀÌ´Ù. 1962³â ÄÍÇÁ(Kempe)¿¡ ÀÇÇØ ¸í¸íµÇ¾ú´Ù. »óó¸¦ ¹ÞÀº ½Ã±â°¡ ¼·Î Â÷À̰¡ ÀÖ´Â ¿Ü»óÀÌ ¸ö Àüü ¿©·¯ °÷¿¡¼ °üÂûµÇ´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ÇǺÎÀÇ ¼Õ»ó°ú ¾ó·èÃâÇ÷, °æÁú¸·ÇÏ Ç÷Á¾, °ñÀý µîÀÌ ¸¹°í ±Ø´ÜÀûÀÎ °æ¿ì´Â ¿µ±¸Àû ³ú¼Õ»ó°ú Á×À½¿¡ À̸£´Â °æ¿ìµµ ÀÖ´Ù. Çд뵿±â´Â ÇÇÇØÀÚ ÀÔÀå¿¡¼´Â À°Ã¼Àû-Á¤½ÅÀû ¹ßÀ°ºÎÀü, ½ÖµÕÀÌ, ±âÇü, ¹ãÁß¿¡ ¿ì´Â °Í, ¾ß´¢Áõ, Àå³, ¹ÝÇ×Àû ŵµ µîÀÌ ÀÖÀ¸¸ç °¡ÇØÀÚ ÀÔÀå¿¡¼´Â º¸À°ÀÚÀÇ ¾ÆÀÌ¿¡ ´ëÇÑ ¾ÖÁ¤°áÇ̰ú °úÀ× ±â´ë, À°¾Æ¿¡ ´ëÇÑ ¹«Áö, ÇüÁ¦Àڸſ¡ ´ëÇÑ ½Ã»ù, Á¤½Åº´, ½Å°æÁõ, Áö´ÉÀúÇÏ, ¾ËÄÚ¿Ã Áßµ¶ µîÀÌ ÀÖ°í, ¶Ç »ýȰȯ°æÀÇ ÀÔÀå¿¡¼´Â ºó°ï, ºÎºÎ ºÒÈ, ÇÙ°¡Á·ÀÌ¸é¼ »çȸÀûÀ¸·Î °í¸³µÈ °¡Á¤ µîÀ» µé ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | severe acute respiratory syndrome(SARS) | ÇÑ±Û | »ç½º |
|---|---|---|---|
| ¼³¸í | Áß±¹ ±¤µ¿ Áö¿ª¿¡¼ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼º È£Èí±â ÁúȯÀ¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â ȯÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â ħ¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀÇ È£Èí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. ħ¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇÏ´Ù´Â ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. |
||
| ¿µ¹® | congenital rubella syndrome | ÇÑ±Û | ¼±ÃµÇ³ÁøÁõÈıº |
|---|---|---|---|
| ¼³¸í | ÀӽűⰣ Áß¿¡ »ê¸ð°¡ dzÁø¿¡ °É¸®¸é ÀÌ Ç³Áø ¹ÙÀÌ·¯½º´Â ŹÝÀ» ÅëÇØ¼ žƿ¡°Ô Àü´ÞµÇ¾î¼ žÆÀÇ Ç³Áø°¨¿°À» ÀÏÀ¸Å²´Ù. ÀӽŠù 3°³¿ù µ¿¾È, ƯÈ÷ ÀӽŠù´Þ¿¡ žư¡ dzÁøÀÇ °¨¿°À» ¹ÞÀ¸¸é, ½Å»ý¾Æ¿¡¼ ¼±Ãµ±âÇü, Áï ´«¿¡¼ ÃÐÁ¡À» Á¤È®È÷ ¸ÂÃß¾îÁÖ´Â ·»ÁîÀÇ ¿ªÇÒÀ» ÇÏ´Â ¼öÁ¤Ã¼ÀÇ È¥Å¹(¹é³»Àå), ½ÉÀå±âÇü, ±Í¸Ó°Å¸® ¹× ½ÉÇÑ Áö´É¹Ú¾àÀ» µ¿¹ÝÇÏ´Â ¼ÒµÎÁõ µîÀÌ ¹ß»ýÇÏ´Â ¼ö°¡ ¸¹´Ù. |
||
| HIV-2 protease | <enzyme> Processes hiv-1pr53(gag) and analogous junction peptides in vitro; less than 60% amino acid identity to hiv-1 protease Registry number: EC 3.4.23.- Synonym: hiv2 protease (26 Jun 1999) |
|---|---|
| HIV-2 reverse transcriptase | <enzyme> Responsible for synthesis of double-stranded DNA from the genomic RNA of the virus; has rnase h and DNA-dependent DNA polymerase activities; was indexed as reverse transcriptase (87-91) Registry number: EC 2.7.7.- (26 Jun 1999) |
| HIV antibodies | Antibodies reactive with human immunodeficiency virus (HIV, previously called HTLV-III/lav) antigens of aids. This includes HIV-1 antibodies and HIV-2 antibodies. (12 Dec 1998) |
| HIV antigens | Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (lav) antigens. (12 Dec 1998) |
| HIV core protein p24 | A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by elisa and western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines. (12 Dec 1998) |
| HIV encephalopathy | <immunology> A frequent cerebral condition in people with AIDS that results in the loss of cognitive capacity, affecting the ability to function in a social or occupational setting. Its cause has not been determined exactly, but may result from HIV infection of cells in the brain or an inflammatory reaction to such infection. (09 Oct 1997) |
| HIV enhancer | Cis-acting regulatory sequences in the HIV long terminal repeat (ltr) which play a major role in induction or augmentation of HIV gene expression in response to environmental stimuli such as mitogens, phorbol esters, or other viruses. The HIV enhancer is the binding site for many cellular transcription factors including the nuclear factor nf-kappa b. (12 Dec 1998) |
| HIV enteropathy | Chronic, well-established diarrhoea (greater than one month in duration) without an identified infectious cause after thorough evaluation, in an HIV-positive individual. It is thought to be due to direct or indirect effects of HIV on the enteric mucosa. HIV enteropathy is a diagnosis of exclusion and can be made only after other forms of diarrhoeal illness have been ruled out. (12 Dec 1998) |
| HIV envelope protein gp120 | External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120,000 kD and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably t4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV. (12 Dec 1998) |
| HIV envelope protein gp160 | An envelope protein of the human immunodeficiency virus that is encoded by the HIV env gene. It has a molecular weight of 160,000 kD and contains numerous glycosylation sites. It serves as a precursor for both the HIV envelope protein gp120 and the HIV envelope protein gp41. (12 Dec 1998) |
| HIV envelope protein gp41 | Transmembrane envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The n-terminal part of gp41 is thought to be involved in cell fusion with the CD4 antigens of t4 lymphocytes, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by immunoblotting. (12 Dec 1998) |
| HIV infections | Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru aids-related complex (arc), to acquired immunodeficiency syndrome (aids). (12 Dec 1998) |
| HIV integrase | <enzyme> Enzyme of the human immunodeficiency virus that is required to integrate viral DNA into cellular DNA in the nucleus of a host cell. HIV integrase is a DNA nucleotidyltransferase encoded by the pol gene. Registry number: EC 2.7.7.- (12 Dec 1998) |
| HIV integrase inhibitors | Inhibitors of HIV integrase, an enzyme required for integration of viral DNA into cellular DNA. (12 Dec 1998) |
| HIV long-terminal repeat | Regulatory sequences important for viral replication that are located on each end of the HIV genome. The ltr includes the HIV enhancer, promoter, and other sequences. Specific regions in the ltr include the negative regulatory element (nre), nf-kappa b binding sites , sp1 binding sites, tata box, and trans-acting responsive element (tar). The binding of both cellular and viral proteins to these regions regulates HIV transcription. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|